Natural product-based therapy for pulmonary arterial hypertension: Berberine inhibits the development of pulmonary arterial hypertension via down regulation of its target gene, 24/March/2014, 07.17 am

Molecular therapy for Miscarriage: Lin-28, the RNA binding protein, may inhibit early pregnancy loss and promote fetal growth via down regulation of its target gene, 23/March/2015, 22.26
March 23, 2015
Molecular therapy for Metabolic diseases: TAp63 decreases blood pressure and inhibits congestive heart failure via down regulation of angiotensin-converting enzyme (ACE) expression, 24/March/2015, 8.58 am
March 24, 2015
Show all

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine; & I.F: 28.054] by Prof. Thistlethwaite PA, Li X and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for pulmonary arterial hypertension: Berberine inhibits the development of pulmonary arterial hypertension via down regulation of its target gene. Together, pharmacological formulations encompassing “Berberine or its analogues” may be used to treat pulmonary arterial hypertension.

Amount: $ 500

Undisclosed information: How Berberine decreases pulmonary arterial hypertension

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Molecular therapy for pulmonary arterial hypertension: Berberine inhibits the development of pulmonary arterial hypertension via down regulation of its target gene, 24/March/2014,  07.17 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.